LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 226

Search options

  1. Article ; Online: Increasing trend of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV.

    Muccini, Camilla / Galli, Laura / Sampaolo, Michela / Gianotti, Nicola / Castagna, Antonella / Canetti, Diana

    The Journal of antimicrobial chemotherapy

    2023  Volume 78, Issue 5, Page(s) 1314–1315

    MeSH term(s) Humans ; HIV Integrase Inhibitors/pharmacology ; HIV Integrase Inhibitors/therapeutic use ; HIV Infections/drug therapy ; Drug Resistance, Viral ; HIV Integrase/genetics ; Mutation
    Chemical Substances HIV Integrase Inhibitors ; HIV Integrase (EC 2.7.7.-)
    Language English
    Publishing date 2023-04-08
    Publishing country England
    Document type Letter
    ZDB-ID 191709-2
    ISSN 1460-2091 ; 0305-7453
    ISSN (online) 1460-2091
    ISSN 0305-7453
    DOI 10.1093/jac/dkad109
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1197: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 124: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Switching antiretrovirals in older patients.

    Gianotti, Nicola / Castagna, Antonella

    The lancet. HIV

    2019  Volume 6, Issue 10, Page(s) e640–e641

    MeSH term(s) Adenine/analogs & derivatives ; Aged ; Bone Density ; Cobicistat ; Emtricitabine ; HIV Infections ; HIV-1 ; Humans ; Middle Aged ; Quinolones ; Tablets ; Tenofovir
    Chemical Substances Quinolones ; Tablets ; elvitegravir (4GDQ854U53) ; Tenofovir (99YXE507IL) ; tenofovir alafenamide (EL9943AG5J) ; Emtricitabine (G70B4ETF4S) ; Adenine (JAC85A2161) ; Cobicistat (LW2E03M5PG)
    Language English
    Publishing date 2019-09-30
    Publishing country Netherlands
    Document type Journal Article ; Comment
    ISSN 2352-3018
    ISSN (online) 2352-3018
    DOI 10.1016/S2352-3018(19)30229-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Outcome of Darunavir-Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure.

    Alberton, Francesca / Galli, Laura / Lolatto, Riccardo / Candela, Caterina / Gianotti, Nicola / Chiurlo, Matteo / Ranzenigo, Martina / Strano, Martina / Uglietti, Alessia / Castagna, Antonella

    Drug design, development and therapy

    2024  Volume 18, Page(s) 1153–1163

    Abstract: Objective: To evaluate the virological outcome of darunavir-cobicistat (DRVc)-based regimens in adults living with HIV who had experienced virological failure (VF) on any previous drug combination.: Methods: This was a retrospective cohort study ( ... ...

    Abstract Objective: To evaluate the virological outcome of darunavir-cobicistat (DRVc)-based regimens in adults living with HIV who had experienced virological failure (VF) on any previous drug combination.
    Methods: This was a retrospective cohort study (CSLHIV Cohort) of adults living with HIV who started a DRVc-based regimen with HIV-RNA >50 copies/mL after VF on any previous drug combination. Data on demographics, antiretroviral treatment since HIV diagnosis, and immunological and metabolic parameters from baseline (start of DRVc) to 48 weeks were analyzed in order to assess the cumulative proportion of those who achieved virological success (VS), defined as at least one instance of HIV-RNA <50 copies/mL within 12 months from baseline. Follow-up lasted from the start of the DRVc-based regimen (baseline) to the first instance of HIV-RNA <50 copies/mL, last available visit, or loss to follow-up or death, whichever occurred first. Univariate and multivariate Cox proportional-hazard regression models were used to identify baseline factors associated with VS.
    Results: A total of 176 individuals were included, and 120 (68.2%) achieved <50 HIV-RNA copies/mL within 12 months since baseline. On multivariate analysis, baseline HDL cholesterol was independently associated with the occurrence of VS (adjusted HR 1.021, 95% CI 1.004-1.038;
    Conclusion: Most individuals in this study achieved VS within 12 months from the beginning of a DRVc-based regimen; therefore, this treatment represent a viable option for people who have experienced VF on other regimens.
    MeSH term(s) Adult ; Humans ; Retrospective Studies ; Drug Combinations ; HIV Protease Inhibitors/therapeutic use ; RNA ; HIV Infections/drug therapy ; Darunavir ; Cobicistat
    Chemical Substances cobicistat mixture with darunavir ; Drug Combinations ; HIV Protease Inhibitors ; RNA (63231-63-0) ; Darunavir (YO603Y8113) ; Cobicistat (LW2E03M5PG)
    Language English
    Publishing date 2024-04-10
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2451346-5
    ISSN 1177-8881 ; 1177-8881
    ISSN (online) 1177-8881
    ISSN 1177-8881
    DOI 10.2147/DDDT.S443775
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions.

    Rusconi, Stefano / Santoro, Maria M / Capetti, Amedeo F / Gianotti, Nicola / Zazzi, Maurizio

    International journal of antimicrobial agents

    2022  Volume 60, Issue 3, Page(s) 106627

    Abstract: HIV infection is currently managed as a chronic disease because of improvements in antiretroviral therapy (ART). Switching to a new regimen is a natural event during long-term therapy to avoid problems related to toxicity, adherence, failure, and ... ...

    Abstract HIV infection is currently managed as a chronic disease because of improvements in antiretroviral therapy (ART). Switching to a new regimen is a natural event during long-term therapy to avoid problems related to toxicity, adherence, failure, and potential selection of drug resistance. The development of co-formulations of multiple agents in one pill, and novel drug classes and drugs with a high genetic barrier to resistance have been important in this context. The approval of the long-acting, once-monthly or bimonthly injectable combination of the second-generation strand transfer integrase inhibitor (InSTI), cabotegravir (CAB) together with the non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (RPV) represents the most recent achievement in the search for potent and convenient ART. Several pivotal trials (such as LATTE-2, ATLAS, FLAIR, and ATLAS-2M) showed the high efficacy and safety of this long-acting formulation used as an induction-maintenance strategy. Few confirmed virological failures (CVF) have been observed. The combination of at least two of the following baseline factors, HIV-1 subtype A6/A1, a body mass index (BMI) ≥30 kg/m
    MeSH term(s) Anti-HIV Agents/adverse effects ; Diketopiperazines ; HIV Infections/drug therapy ; HIV-1 ; Humans ; Pyridones/therapeutic use ; Rilpivirine/therapeutic use
    Chemical Substances Anti-HIV Agents ; Diketopiperazines ; Pyridones ; Rilpivirine (FI96A8X663) ; cabotegravir (HMH0132Z1Q)
    Language English
    Publishing date 2022-06-24
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2022.106627
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3368: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 500: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Mpox Virus: Control of In-Hospital Occupational Transmission Experience from a Tertiary Level Hospital in Milan, Italy.

    Raccagni, Angelo Roberto / Gianotti, Nicola / Moro, Matteo / Mileto, Davide / Gordo Perez, Victoria / Castagna, Antonella / Nozza, Silvia

    Life (Basel, Switzerland)

    2023  Volume 13, Issue 8

    Abstract: Mpox has caused a global outbreak since May 2022, particularly affecting people belonging to key populations, but cases among healthcare providers have been reported. The aim of this work is to present the experience of the Infectious Diseases Unit of ... ...

    Abstract Mpox has caused a global outbreak since May 2022, particularly affecting people belonging to key populations, but cases among healthcare providers have been reported. The aim of this work is to present the experience of the Infectious Diseases Unit of San Raffaele Scientific Institute, Milan, Italy with respect to infection control and prevention of mpox occupational transmission. Between May-November 2022, 140 individuals were diagnosed with mpox and six required hospitalization. Overall, 12 medical doctors and 22 nurses provided care to people with mpox. A hospital policy aimed at controlling viral transmission was implemented in May 2022. Protective equipment was used for all healthcare providers. One accidental puncture occurred with a scalpel contaminated with blood from a mpox viremic individual (mpox plasma cycle threshold = 36); no mpox related symptoms were observed and mpox testing ruled out transmission. Six months following exposure, neutralizing antibodies were not detectable, ruling out contagion. Overall, we observed no mpox transmission among healthcare workers, despite the number of visits and procedures performed, including bodily-fluids sampling, and even following puncture with contaminated blood. Hospital preparedness for the management of new infectious disease outbreaks, with rapid implementation of policies aimed at controlling infection, is paramount to avoid occupational transmission.
    Language English
    Publishing date 2023-08-08
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662250-6
    ISSN 2075-1729
    ISSN 2075-1729
    DOI 10.3390/life13081705
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Failure of on-demand pre-exposure prophylaxis: the risk of HIV drug resistance.

    Raccagni, Angelo Roberto / Bruzzesi, Elena / Gianotti, Nicola / Sampaolo, Michela / Canetti, Diana / Castagna, Antonella / Nozza, Silvia

    Sexually transmitted infections

    2022  Volume 98, Issue 3, Page(s) 234

    MeSH term(s) Anti-HIV Agents/therapeutic use ; Drug Resistance ; HIV Infections/drug therapy ; HIV Infections/prevention & control ; Humans ; Pre-Exposure Prophylaxis
    Chemical Substances Anti-HIV Agents
    Language English
    Publishing date 2022-01-17
    Publishing country England
    Document type Letter
    ZDB-ID 1420303-0
    ISSN 1472-3263 ; 1368-4973
    ISSN (online) 1472-3263
    ISSN 1368-4973
    DOI 10.1136/sextrans-2021-055354
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.108: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: The future of long-acting cabotegravir plus rilpivirine therapy: Deeds and misconceptions

    Rusconi, Stefano / Santoro, Maria M. / Capetti, Amedeo F. / Gianotti, Nicola / Zazzi, Maurizio

    International journal of antimicrobial agents. 2022 June 19,

    2022  

    Abstract: HIV infection is currently managed as a chronic disease thanks to the improvement of antiretroviral therapy (ART). In this light, treatment is lifelong. Therefore, switch to new regimens is a natural event during long-term therapies to avoid problems ... ...

    Abstract HIV infection is currently managed as a chronic disease thanks to the improvement of antiretroviral therapy (ART). In this light, treatment is lifelong. Therefore, switch to new regimens is a natural event during long-term therapies to avoid problems related to toxicity, adherence, failure and potential selection of drug resistance. In this context, coformulations of multiple agents in one pill and the development of novel drug classes and drugs with high genetic barrier to resistance are now available. The recent approval of the long-acting once monthly or bimonthly injectable combination of the second-generation strand transfer integrase inhibitor (InSTI) cabotegravir (CAB) together with the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) represents the most recent achievement along the line of potent and convenient ART. Several pivotal trials (such as LATTE-2, ATLAS, FLAIR, and ATLAS-2M) largely demonstrated the high efficacy and safety of this long-acting formulation used as an induction-maintenance strategy. Few confirmed virological failures (CVF) have been observed. The combination of at least two baseline factors among HIV-1 subtype A6/A1, a body mass index ≥30 kg/m², and RPV resistance associated mutations, was associated with an increased risk of CVF at week 48. Available data indicate that this long-acting therapeutic strategy is attractive and potent, thus defining the most appropriate patient and how to handle practical issues is warranted.
    Keywords HIV infections ; RNA-directed DNA polymerase ; antiretroviral agents ; body mass index ; chronic diseases ; drug resistance ; integrase inhibitors ; patients ; risk ; therapeutics ; toxicity
    Language English
    Dates of publication 2022-0619
    Publishing place Elsevier Ltd
    Document type Article
    Note Pre-press version
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2022.106627
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3368: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 500: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Achieving virological control in pan-resistant HIV-1 infection: A case series.

    Canetti, Diana / Muccini, Camilla / Spagnuolo, Vincenzo / Galli, Laura / Poli, Andrea / Gianotti, Nicola / Feasi, Marcello / Castagna, Antonella

    EBioMedicine

    2022  Volume 77, Page(s) 103906

    Abstract: Background: HIV-1 pan-resistance refers to a reduced susceptibility to nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors and integrase strand tranfer inhibitors. Although still anecdotal, ... ...

    Abstract Background: HIV-1 pan-resistance refers to a reduced susceptibility to nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors and integrase strand tranfer inhibitors. Although still anecdotal, its management remains a concern both for affected people living with HIV (PLWH) and for public health.
    Methods: We described genotypic resistance testing (GRT) of three PLWH with a documented poor virological response to previous antiretroviral therapies, who started ibalizumab, an anti-CD4 monoclonal antibody, combined with an optimized background therapy. Both historical and most recent GRT on plasma RNA and peripheral blood mononuclear cell DNA were interpreted according to the Stanford HIVDb version 9.0 (last updated on 22 February, 2021). After the switch to a regimen including the monoclonal antibody, HIV-1 RNA has been quantified biweekly (PCR Cobas® HIV-1 test 6800 Systems, Roche Diagnostics). Follow-up was censored at data freezing (16 January, 2021).
    Findings: We report findings from heavily treatment-experienced PLWH with a pan-resistant HIV-1 infection, who achieved virological control once introduced injections of ibalizumab, that is free from cross-resistance with all the antiretroviral drugs available and ensures patient adherence due to a close monitoring attributable to the route of administration, combined with recycled enfuvirtide and an optimized background regimen, selected on the basis of an accurate evaluation of resistance mutations.
    Interpretation: In these cases, this new approach has revealed to be a turning point in achieving virological control.
    Funding: None, this research was supported by internal funding.
    MeSH term(s) Anti-HIV Agents/pharmacology ; Anti-HIV Agents/therapeutic use ; Drug Resistance, Viral/genetics ; HIV Infections/drug therapy ; HIV-1/genetics ; Humans ; Leukocytes, Mononuclear ; Reverse Transcriptase Inhibitors/therapeutic use ; Viral Load
    Chemical Substances Anti-HIV Agents ; Reverse Transcriptase Inhibitors
    Language English
    Publishing date 2022-03-04
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2851331-9
    ISSN 2352-3964
    ISSN (online) 2352-3964
    DOI 10.1016/j.ebiom.2022.103906
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7090: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Chilblain-like lesions in children following suspected COVID-19 infection.

    Colonna, Cristiana / Monzani, Nicola Adriano / Rocchi, Alessia / Gianotti, Raffaele / Boggio, Francesca / Gelmetti, Carlo

    Pediatric dermatology

    2020  Volume 37, Issue 3, Page(s) 437–440

    Abstract: During the COVID-19 pandemic, chilblain-like lesions have been reported in mildly symptomatic children and adolescents. We present four children investigated for suspected COVID-19 infection who presented with acral skin findings and mild systemic ... ...

    Abstract During the COVID-19 pandemic, chilblain-like lesions have been reported in mildly symptomatic children and adolescents. We present four children investigated for suspected COVID-19 infection who presented with acral skin findings and mild systemic symptoms. Histology from one case showed signs of vasculitis with evident fibrin thrombus.
    MeSH term(s) Betacoronavirus ; COVID-19 ; Chilblains/diagnosis ; Chilblains/virology ; Child ; Child, Preschool ; Coronavirus Infections/complications ; Coronavirus Infections/pathology ; Female ; Humans ; Male ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/pathology ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-06-01
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 605539-4
    ISSN 1525-1470 ; 0736-8046
    ISSN (online) 1525-1470
    ISSN 0736-8046
    DOI 10.1111/pde.14210
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1882: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic.

    Papaioannu Borjesson, Rebecka / Galli, Laura / Muccini, Camilla / Poli, Andrea / Clemente, Tommaso / Bottanelli, Martina / Gianotti, Nicola / Nozza, Silvia / Castagna, Antonella / Spagnuolo, Vincenzo

    Frontiers in medicine

    2023  Volume 10, Page(s) 1220631

    Abstract: Introduction: The aim of this study was to analyze the impact of COVID-19 pandemic restrictions on the prevalence and incidence of metabolic syndrome (MS), and to identify predictors of new MS cases in people living with HIV (PLWH).: Methods: This ... ...

    Abstract Introduction: The aim of this study was to analyze the impact of COVID-19 pandemic restrictions on the prevalence and incidence of metabolic syndrome (MS), and to identify predictors of new MS cases in people living with HIV (PLWH).
    Methods: This cohort study included PLWH followed at the IRCCS San Raffaele, Milan, Italy, with at least one body mass index (BMI) determination during the pre-pandemic period (1 December 2018 to 29 February 2020) and the pandemic period (1 March 2020 to 31 May 2021). MS diagnosis was based on NCEP ATP III 2005 criteria. Univariable Poisson regression model was used to compare MS incidence rates. Univariable mixed linear models estimated the crude mean change in metabolic parameters during each time period. Multivariable Cox proportional hazards model was used to assess risk factors for MS.
    Results: This study included 1,564 PLWH, of whom 460 and 1,104 were with and without a diagnosis of MS, respectively, at the beginning of the pre-pandemic period, with an overall prevalence of MS of 29.4%. During the pre-pandemic period, 528/1,564 PLWH had MS, with a prevalence of 33.8% (95%CI = 31.5%-36.1%), while during the pandemic period, the number of PLWH with a diagnosis of MS increased to 628/1,564, with a prevalence of 40.2% (95%CI 37.8%-42.6%; McNemar's test:
    Conclusion: The COVID-19 pandemic affected the metabolic profile of PLWH and increased the prevalence and incidence of MS.
    Language English
    Publishing date 2023-09-18
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2023.1220631
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top